BNET Industries

Market Cap:$2.2B
Last Fiscal Year Sales:$842.8M
  • Public
  • CA
Dow Jones Description

Mfr. of Pharmaceuticals & Drug Delivery Systems

Chief Executive Officer
Bruce D. Brydon
Number of Employees 1,368
Contact Information

7150 Mississauga Rd

Mississauga, Ontario L5N 8M5

www.biovail.com

(905) 286-3000

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Biovail net income falls to $40.4 million US

    11/06/09 - Financial Announcement - View Story

  • BRIEF-RESEARCH ALERT-Credit Suisse raises targets on Alcon, 9 others

    10/16/09 - Bond / Stock Rating - View Story

  • Biovail, Acadia To Contiune Development Of Pimavanserin Program For Parkinson's

    10/06/09 - Joint Venture / Alliance - View Story

  • ACADIA Pharmaceuticals ACAD Shares Rise Sharply on Pimavanserin Update

    10/06/09 - Bond / Stock Rating - View Story

  • Techs tank in T.O.

    9/28/09 - Bond / Stock Rating - View Story

  • Biovail Corporation BVF Settles Cardizem Case with $22.2 Million Fine 9/15/2009

    9/15/09 - Legal Settlement - View Story

  • Biovail BVF Upgraded By Credit Suisse

    9/14/09 - Bond / Stock Rating - View Story

  • RPT-STOCKS NEWS US-Bulls bet on Kroger before earnings-analyst

    9/14/09 - Bond / Stock Rating - View Story

  • Credit Suisse Upgrades Biovail BVF to Outperform

    9/14/09 - Bond / Stock Rating - View Story

  • Biovail stumbles on Phase III testing for Parkinson's drug

    9/02/09 - Joint Venture / Alliance - View Story

  • Biovail disappointed by clinical trial of drug to treat Parkinsons psychosis

    9/01/09 - Bond / Stock Rating - View Story

  • Week of Aug. 24, 2009: Warner Chilcott Buys P&G Pharma Business; Amylin Appoints Former Novartis...

    8/27/09 - Joint Venture / Alliance - View Story

  • Biovail, Santhera strike Parkinson's drug deal

    8/24/09 - Joint Venture / Alliance - View Story

  • Biovail to Purchase Rights to Develop and Commercialize JP-1730/Fipamezole in North America

    8/26/09 - Joint Venture / Alliance - View Story

  • Judge Dismisses Biovails Suit Against Hedge Fund

    8/20/09 - Legal Settlement - View Story

  • Drug maker Biovail reverses year-ago loss

    8/07/09 - Financial Announcement - View Story

News & Analysis

agreement and biovail corp. - All News and Analysis

Decision Makers

Name (plus bio) Position
Bruce D. Brydon Chief Executive Officer
William M. Wells Chief Executive Officer, Director
Eugene N. Melnyk President Bls
Gilbert Godin Executive Vice President and Chief Operating Officer
Kenneth C. Cancellara Chief Legal Officer, Senior Vice President & Secretary
Kenneth G. Howling Senior Vice President and Chief Financial Officer
Mark Durham Chief Operating Officer
Peggy Mulligan Senior Vice President, Chief Financial Officer
Brian H. Crombie Senior Vice President
Christine Mayer Senior Vice President, Business Development Services
David R. Keefer Senior Vice President, Commercial Operations
Gregory D. Gubitz Senior Vice President, Corporate Development
Gregory Szpunar Senior Vice President, Res
Michael Yeomans Senior Vice President, Business Development
Peter Silverstone Senior Vice President, Medical & Scientific Affairs
Rolf K. Reininghaus Senior Vice President
Wendy A. Kelley General Counsel, Senior Vice President & Secretary
Adrian De Saldanha Vice President & Treasurer
Christopher Bovaird Vice President
Douglas Herman General Counsel & Vice President
Greg Guyatt Vice President, Controller
Jennifer Tindale Vice President and Associate General Counsel
John R. Miszuk Vice President, Controller & Assistant Secretary
John Sebben Vice President, Manufacturing
Kathleen Brown Assoc General Counsel, Vice President
Nelson F Isabel Vice President, Investor Relations & Corporate Communications
Patrick D. Dwyer Vice President, Manufacturing
John Allport Counsel
David H Laidley Director
J. Spencer Lanthier Director
Laurence E. Paul Director
Mark Parrish Director
Robert A. Paul Director
Robert N Power Director
Serge Gouin Director

Board of Directors

Name (plus bio) Position
Douglas J.P. Squires Chairman
Jamie C. Sokalsky Board of Directors
Lloyd M. Segal Board of Directors
Michael R. Van Every Board of Directors
Roger R. Rowan Board of Directors
Wilfred G. Bristow Board of Directors

Organization Position Status
Biovail Corporation Chief Executive Officer Current
Biovail Corporation President Former
ViRexx Medical Corp. Director Former

Mr. Wells is our Chief Executive Officer and President of Biovail Laboratories International SRL, positions he has held since May 1, 2008. Mr. Wells was elected to the Board of Directors in June 2005. Mr. Wells served as the Lead Director of the Board from June 30, 2007 to April 18, 2008. Prior to joining us on May 1, 2008, Mr. Wells was the Chief Financial Officer of Loblaw Companies Limited, Canada's largest food distributor and a leading provider of general merchandise products, drugstore products, and financial products and services a position from which he resigned immediately prior to joining Biovail as our Chief Executive Officer. Mr. Wells also served as a director or officer of a number of subsidiaries of Loblaw. Prior to his position at Loblaw, Mr. Wells served as Chief Financial Officer of Bunge Limited, a U.S.-headquartered company, whose shares are listed on the NYSE, in the global agribusiness, fertilizer and food product industries, and has served as a director or officer of a number of other subsidiaries and joint ventures of Bunge since January 2000. Mr. Wells is versed in corporate governance matters, having led Bunge's initial public offering on the NYSE, managed its SOX compliance process and overseen its investor relations program. Prior to joining Bunge, Mr. Wells spent ten years in senior financial management at McDonald's Corporation in theU.S. and Brazil. Mr. Wells is currently a Trustee and a member of the audit committee of the Lakefield College School Foundation, a member of the investment committee of the Uruguay International Venture Capital Fund and formerly a member of the Standard & Poor's Corporate Issuer Advisory Board. Mr. Wells is a member of our Risk and Compliance Committee. Mr. Wells is based in Barbados.

Organization Position Status
Biovail Corporation Chief Executive Officer, Director Current
Loblaw Companies Limited Chief Financial Officer Current
Biovail Corporation Board of Directors Current
Bunge Limited Chief Financial Officer Former
McDonald's Corporation Former

Organization Position Status
Biovail Corporation President Bls Current
Ontario Hockey League Owner Current
Biovail Corporation Executive Chairman Current
Providence Elementary School Board of Directors Current
Help US Help The Children Board of Directors Current
Sens Foundation Board Member Current
The Belmont Childcare Association Board of Directors Current
Biovail Corporation Founder Former
Biovail Corporation Board of Directors Former

As Executive Vice-President, COO, Gilbert Godin oversees Biovail's operational functions, product-development capability, manufacturing and contract-development services, as well as business-development services. He joined Biovail in April 2006 as Senior Vice-President, Technical Operations/Drug Delivery. Mr. Godin came to Biovail from MDS Pharma Services, where he held a series of progressively responsible executive positions in Canada and the United States. From October 2004, he served as President of MDS Pharma, a contract research organization that provides drug-discovery and development services to pharmaceutical and biotechnology companies. Before joining MDS in 1999, Mr. Godin spent eight years with Schering Plough, where he held the technical leadership position in Canada, and a business-unit management role in France . He has also held several positions with business and operational accountabilities during his seven-year tenure at L'Oreal Canada. Mr. Godin has a Masters degree in Business Administration from Concordia University in Montreal. He also holds an engineering degree from Sherbrooke University in Quebec.

Organization Position Status
Biovail Corporation Executive Vice President and Chief Operating Officer Current
Schering-Plough Corporation Former
Concordia University M.B.A. Former
Sherbrooke University Degree Former

Organization Position Status
Biovail Corporation Chief Legal Officer, Senior Vice President & Secretary Current

Organization Position Status
Biovail Corporation Senior Vice President and Chief Financial Officer Current
Biovail Corporation Vice President, Finance Former

As Senior Vice-President, Human Resources & Shared Services, Mark Durham oversees Biovail's Human Resources, internal communications, procurement and office-based facilities functions. Mr. Durham joined Biovail as Vice-President, Corporate Human Resources in 2003. He came to Biovail from Pharmacia Corporation, where he served as Vice-President, Human Resources for Global Marketing and North American country operations from 2000-2003. Previously, he spent 15 years with Pharmacia and Upjohn, and held senior Human Resources positions in the United States, Asia and Canada. In addition to Human Resources, Mr. Durham has held positions in Manufacturing and Sales Operations. Mr. Durham holds a B.A. Hons. degree in Political Science and Economics from Carleton University in Ottawa.

Organization Position Status
Biovail Corporation Chief Operating Officer Current
Biovail Corporation Senior Vice President, Shared Services Former
Biovail Corporation Vice President, HR Former

Peggy Mulligan serves as Senior Vice-President and Chief Financial Officer (CFO) of Biovail Corporation. As such, Mrs. Mulligan oversees all of Biovail's financial operations, and is responsible for Internal Audit and Information Technology. Mrs. Mulligan was most recently a Principal at Priiva Consulting Corporation, a leading game theory consulting practice. Prior to that, she served as Executive Vice-President, Chief Financial Officer and Treasurer of Linamar Corporation from 2005 to 2007. Prior to Linamar, Mrs. Mulligan spent more than eleven years with The Bank of Nova Scotia (Scotiabank), most recently as Executive Vice-President, Systems and Operations, where she was responsible for operational processes and technology across Canada and in more than 50 other markets. She directed a staff of over 3,000 and managed a broad range of critical information-technology functions. Earlier in her career at Scotiabank, Mrs. Mulligan served as Senior Vice-President, Audit & Chief Inspector. Before joining Scotiabank, Mrs. Mulligan was an Audit Partner with PricewaterhouseCoopers in Toronto . Mrs. Mulligan currently serves on the boards of Ontario Power Generation Inc. and Resolve Business Outsourcing Income Fund. Her extensive community involvement has included serving as a Trustee of the Ontario Science Centre, a Governor of Appleby College and a Governor of the University of Waterloo. Mrs. Mulligan holds a B.Math (Honours) from the University of Waterloo and was named a Fellow Chartered Accountant (FCA) by the Institute of Chartered Accountants of Ontario in 2003.

Organization Position Status
Biovail Corporation Senior Vice President, Chief Financial Officer Current

Organization Position Status
Biovail Corporation Senior Vice President Current

As Senior Vice-President, Business Development Services, Biovail Pharmaceuticals, Inc. Christine Mayer is responsible for leading the Business Development Services team, which provides services in respect of identifying and analyzing new opportunities for the Company. Ms. Mayer joined Biovail in May 2005, and was promoted to her current title effective January 1, 2007. She has over 20 years of broad business experience in the pharmaceutical industry across many disciplines and therapeutic areas. Before joining Biovail, she held the position of Vice-President of Global Business Development at Sanofi-Aventis (formerly Aventis), where she spent five years. Prior to that, she worked for 13 years at Johnson & Johnson in the pharmaceutical sector, holding many positions in various disciplines, including Business Development, Marketing, Sales and Finance. Ms. Mayer also has four years of previous experience in large public accounting firms. Ms. Mayer holds an M.B.A. from Rutgers University and a B.A. from Glassboro College.

Organization Position Status
Biovail Corporation Senior Vice President, Business Development Services Current

Organization Position Status
Biovail Corporation Senior Vice President, Commercial Operations Current

As Senior Vice-President, Corporate Development, Biovail Corporation, Greg Gubitz investigates growth opportunities and other initiatives that will enable Biovail to maximize the value of current and future investments. He also assists the Company in the strategic-planning process. Mr. Gubitz joined Biovail in March 2006 from MDS Capital Corp., a North American venture-capital company focused exclusively on life sciences, where he was Chief Operating Officer. He spent 10 years with MDS Capital in various senior roles, with accountability for all operational matters, institutional fund-raising, investor relations, finance and legal affairs. Mr. Gubitz also became Chairman of MDS Capital's Investment Committee in 2004. Before joining MDS Capital in 1996, Mr. Gubitz was a partner practising corporate and securities law at Fasken, Martineau Barristers and Solicitors. He was called to the Bar in the Province of Ontario in 1984. Mr. Gubitz holds an LL.B. and a Bachelor of Arts degree from McGill University in Montreal.

Organization Position Status
Biovail Corporation Senior Vice President, Corporate Development Current
MDS Capital COO Former
Fasken Martineau Dumoulin Llp Partner Former
McGill University B.A. Former

Organization Position Status
Biovail Corporation Senior Vice President, Res Current

Organization Position Status
Biovail Corporation Senior Vice President, Business Development Current

Organization Position Status
Biovail Corporation Senior Vice President, Medical & Scientific Affairs Current

Organization Position Status
Biovail Corporation Senior Vice President Current
Biovail Corporation Board of Directors Current

As Senior Vice-President, General Counsel and Corporate Secretary, Wendy Kelley is a member of Biovail's senior management team. She is responsible for Biovail's worldwide legal operations, including corporate governance, securities compliance, mergers and acquisitions, intellectual property, litigation, patent law and legal policies. She also serves as Corporate Secretary to the Board of Directors. Prior to joining Biovail in August 2006, Ms. Kelley was Vice-President, Associate General Counsel and Principal Reputation Risk Officer for BMO Financial Group. Her responsibilities included enterprise-wide responsibility for corporate governance; legal and reputation risk management; regulatory relationship management; and management of all securities litigation and regulatory enforcement issues. Previously, she served as Managing Director and Associate General Counsel for BMO Nesbitt Burns, the broker-dealer and wealth-management firm of BMO Financial Group, where she oversaw all litigation, securities policy development and regulatory enforcement, including management of several large international securities class actions. Previously, she was a lawyer at Torys, LLP, an international law firm. Ms. Kelley received her law degree from Queen's University, Canada and is a graduate of the Advanced Management Program from Harvard Business School.

Organization Position Status
Biovail Corporation General Counsel, Senior Vice President & Secretary Current
Biovail Corporation Board of Directors Current
Torys LLP Lawyer Former
Biovail Corporation General Counsel Former

Organization Position Status
Biovail Corporation Vice President & Treasurer Current

Organization Position Status
Biovail Corporation Vice President Current

Organization Position Status
Biovail Corporation General Counsel & Vice President Current

Organization Position Status
Biovail Corporation Vice President, Controller Current

Organization Position Status
Biovail Corporation Vice President and Associate General Counsel Current

Organization Position Status
Biovail Corporation Vice President, Controller & Assistant Secretary Current

Organization Position Status
Biovail Corporation Vice President, Manufacturing Current

Organization Position Status
Biovail Corporation Assoc General Counsel, Vice President Current

Organization Position Status
Biovail Corporation Vice President, Investor Relations & Corporate Communications Current

Organization Position Status
Biovail Corporation Vice President, Manufacturing Current

Organization Position Status
Intellipharmaceutics Ltd. Vice President, Legal Affairs and Licensing Current
Biovail Corporation Counsel Current
Intellipharmaceutics Ltd. Board of Directors Current

Dr. Squires is the Chairman of the Board. Dr. Squires has served on our Board of Directors since June 29, 2005. From June 30, 2007 to May 1, 2008, Dr. Squires served as Interim Chairman of the Board. Effective May 1, 2008, Dr. Squires was appointed Chairman of the Board. From November 2004 to May 1, 2008, Dr. Squires was our Chief Executive Officer. Before joining Biovail in November 2004, Dr. Squires spent six years at MDS Inc, a publicly traded company on the NYSE and the TSX, the last three as President and Chief Executive Officer of MDS Pharma Services, which provides drug-discovery and development services to pharmaceutical and biotechnology companies. Before joining MDS, Dr. Squires spent more than 22 years with The Upjohn Company and Pharmacia Upjohn Inc., where he held multiple senior positions inCanada, the United States and the Pacific Rim. He received his B.Sc. from the University of Toronto and his Ph.D. in biophysics from the University of London, Institute of Cancer Research.

Organization Position Status
Biovail Corporation Chairman Current
Mds Pharma Services President & CEO Former
Biovail Corporation Chief Executive Officer Former
Pharmacia & Upjohn Former
University of London Ph.D. In Biophysics Former
University of Toronto B.Sc. Former

David Laidley was elected to the Board of Directors in August 2008. Mr. Laidley is a retired partner of Deloite & Touche LLP and served as Chairman of Deloite & Touche LLP from 2000 to 2006. Mr. Laidley is also a director of the Bank of Canada, Aviva Canada Inc., EMCOR Group, Inc., Groupe Aeroplan Inc., ProSep Inc. and is Chairman of Nautilus Indemnity Holdings Limited (Bermuda), a captive insurance company. Mr. Laidley also serves on the boards of the Fraser Institute, the Institute of Corporate Directors, and Pearson College of the Pacific. Mr. Laidley is a Fellow of the Quebec Order of Chartered Accountants and holds a Bachelor of Commerce degree from McGill University. Mr. Laidley is a member of our Nominating and Corporate Governance Committee and a member of our Audit Committee.

Organization Position Status
Biovail Corporation Director Current
Prosep, Ltd Board of Directors Current
TORR Canada Inc. Board of Directors Current
Bank of Canada Board of Directors Current
EMCOR Group, Inc. Board of Directors Current
McGill University Bachelor of Commerce Degree Former

"J. Spencer Lanthier is a distinguished board member and contributor with some of Canada's leading corporations and community organizations. He joined Zarlink's Board of Directors in May 2003. Mr. Lanthier enjoyed a 39-year career with KPMG Canada, serving as Chairman and CEO of the firm's Canadian operations from 1993 until he retired in 1999. Financial Post Magazine repeatedly named him one of Canada's Top 200 CEOs. A recipient of the Order of Canada, Mr. Lanthier is currently a Director of the Boards of the TSX Group, Inc., Bank of Canada, Torstar Corporation, Ellis-Don Inc., BCE Emergis, Gerdau Ameristeel Inc. and Biovail. He is also active with the United Way, Goodwill Industries, The University of Toronto, and the London Health Sciences Foundation. Educated at McGill University, Mr. Lanthier received an honorary Doctor of Law from the University of Toronto in 2002. "

Organization Position Status
Zarlink Semiconductor, Inc. Management Consultant Current
RONA, Inc. Chair Current
EllisDon Corporation Chair Current
Emergis, Inc. Chair Current
Zarlink Semiconductor, Inc. Board Member Current
Torstar Corporation Board of Directors Current
TSX Group, Inc. Board of Directors Current
Biovail Corporation Director Current
BCE Emergis Corporation Director Current
Bank of Canada Director Current
BCE Emergis Corporation Corp Director Former
Emergis, Inc. Board of Directors Former
University of Toronto Doctor, Law Former

Jamie C. Sokalsky assumed the responsibilities of Executive Vice President and Chief Financial Officer of Barrick Gold Corporation in May 2004. Previously, Mr. Sokalsky had been the Senior Vice President and Chief Financial Officer since March 1999 and Vice President and Treasurer, directing the financial operations of the Company including the successful forward sales program, for six years. Mr. Sokalsky has an Honours Bachelor of Commerce degree from Lakehead University, Ontario and received his chartered accountant designation in 1982.

Organization Position Status
Barrick Gold Corporation Executive Vice President and Chief Financial Officer Current
Barrick Gold Corporation Board of Directors Current
Biovail Corporation Board of Directors Current
Barrick Chief Financial Officer Former
Barrick Senior Vice President Former
George Weston Limited Former
Barrick Treasurer Former

Organization Position Status
Gold's Gym Board Member Current
Biovail Corporation Director Current
The American National Red Cross Board of Directors Current
Harvard Medical School Board of Directors Current
Morton's Restaurant Group, Inc. Director Current
Ampco-Pittsburgh Corporation Board of Directors Current
Louis Berkman Co. Vice President Former
Harvard University M.D. Former
Stanford University M.B.A. Former
Stanford Graduate School of Business M.B.A. Former
Harvard University Bachelors Degree Former

Organization Position Status
Resonant Medical Board of Directors Current
Biovail Corporation Board of Directors Current
Ecopia Biosciences Inc. President Former
McKinsey & Company, Inc. Management Consultant Former
SciQuest, Inc. Board of Directors Former
Hallmark Technologies, Inc. Board of Directors Former
Harvard Business School M.B.A. Former
Brandeis University B.A. in Politics Former

Mark Parrish was elected to the Board of Directors in August 2008. Mr. Parrish serves as Chairman and Chief Executive Officer of Mobilex USA and Diagnostic Laboratories, a privately held Long-Term Care services company providing Mobile X-Ray and Laboratory services to Skilled Nursing Facilities nationwide. Additionally, Mr. Parrish is the President of the International Federation of Pharmaceutical Wholesalers and a Senior Advisor, Growth Equity at Frazier Healthcare Ventures. Mr. Parrish was Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health Inc., an $87 billion global manufacturer and distributor of medical and surgical supplies and technologies, publicly traded on the NYSE, from November 2006 to 2007. Cardinal Health?s customers are located on five continents and include hospitals, medical centers, retail and mail-order pharmacies, clinics, physicians, pharmacists and other healthcare providers. Mr. Parrish also served in a number of other roles at Cardinal Health Inc., including as Group President, Pharmaceutical Supply Chain Services from August 2006, President and Chief Operating Officer, Pharmaceutical Supply Chain Services from September 2005 to August 2006, Chairman and Chief Executive Officer, Pharmaceutical Distribution and Provider Services from August 2004 to September 2005, Executive Vice President and Group President, Pharmaceutical Distribution from January 2003 to August 2004 and President, Medicine Shoppe, a subsidiary of Cardinal Health Inc., from July 2001 to January 2003. Mr. Parrish holds a Bachelor of Arts degree from the University of California, Berkley. Mr. Parrish is the Chairperson of our Risk and Compliance Committee and a member of our Compensation Committee.

Organization Position Status
Biovail Corporation Director Current

Michael Van Every was elected to the Board of Directors in June 2004. Mr. Van Every is a retired partner of PricewaterhouseCoopers LLP. From 1969 to 1998, he was a partner of Coopers & Lybrand, one of the predecessor firms of PricewaterhouseCoopers LLP. During that period, he served for various periods as Partner in Charge of an office, a member of the Management Committee, a member of the Partnership Board and Chair of the Partnership Audit and Governance Committees. Mr. Van Every is also a member of the boards of Kelman Technologies Inc. (a TSX-listed company) and the Jockey Club of Canada. Mr. Van Every has completed the Director Education Program sponsored by the Rotman School of Management and the Institute of Corporate Directors, and has received his ICD.D, the professional designation for directors in Canada. Mr. Van Every is Chairperson of our Audit Committee and a member of our Risk and Compliance Committee.

Organization Position Status
Biovail Corporation Board of Directors Current

ROBERT A. PAUL (age 71, Director since 1970). Mr. Paul has been Chairman and Chief Executive Officer since March 2004. Prior to March 2004, he was President and Chief Executive Officer of the Corporation for more than five years. He is also the President and a director of The Louis Berkman Investment Company.

Organization Position Status
Ampco-Pittsburgh Corporation CEO Current
Morton's Restaurant Group, Inc. Director Current
Biovail Corporation Director Current
National City Corporation Dividend Committee Member Current
Ampco-Pittsburgh Corporation President Former
Ampco-Pittsburgh Corporation Chairman Former

Robert N. Power was elected to the Board of Directors in August 2008. Mr. Power was most recently the Executive Vice President of Global Business Operations of Wyeth, a global leader in prescription pharmaceuticals, non-prescription consumer health care products, and pharmaceuticals for animal health, which is publicly traded on the NYSE. Wyeth's product portfolio includes innovative treatments across a wide range of therapeutic areas, manufacturing facilities on four continents, and a unique research and technology base encompassing small molecules, biopharmaceuticals and vaccines. Mr. Power has held a number of leadership positions with Wyeth Pharmaceuticals since 1985 including Managing Director U.K., President EMEA and President International. Mr. Power holds a Masters of Science (Biostatistics) degree from the Medical College of Virginia and a Bachelor of Arts (Statistics) degree from S.U.N.Y Oneonta. Mr. Power is a member of our Compensation Committee and a member of our Risk and Compliance Committee.

Organization Position Status
Biovail Corporation Director Current

Organization Position Status
Biovail Corporation Board of Directors Current

Serge Gouin was elected to the Board of Directors in August 2008. Mr. Gouin is Chairman of Quebecor Media Inc., a communications, media and entertainment company. From March 2004 to May 2005, Mr. Gouin was President and Chief Executive Officer of Quebecor Media Inc. In the past five years, Mr. Gouin was also Vice Chairman, Salomon Smith Barney Canada, Inc., a financial services company, until 2003, and advisory director of Citigroup Global Markets Canada Inc., a financial services company, from 2003 to 2004. Mr. Gouin serves as a director of TVA Group Inc., a broadcast communications company, and Chairman of the board of directors of Sun Media Corporation, a newspaper publishing company, and Videotron Limited, a cable television company, all of which are part of the Quebecor group of companies. Mr. Gouin is also a director of Onex Corporation, a conglomerate publicly traded on the TSX. He also serves on the Advisory Committee of the Richard Ivey School of Business. Mr. Gouin holds a Bachelor of Arts degree from the University of Montreal, as well as a Bachelor of Arts degree and Master of Business Administration degree from the Ivey School of Business. Mr. Gouin is a member of our Audit Committee and a member of our Nominating and Corporate Governance Committee.

Organization Position Status
Biovail Corporation Director Current

Organization Position Status
Raymond James Ltd. Financial Advisor Current
Biovail Corporation Board of Directors Current

Executive News

  • Biovail stumbles on Phase III testing for Parkinson's drug

    Globe Investor - 9/02/09 - View Story

  • Biovail disappointed by clinical trial of drug to treat Parkinsons psychosis

    Thunder Bay Chronicle-Journal - 9/01/09 - View Story

  • Biovail 'disappointed' by clinical trial of drug to treat Parkinson's psychosis

    570News - 9/01/09 - View Story

  • STOCKS NEWS US-BMO starts coverage on grocery stores

    Forbes.com - 9/01/09 - View Story

  • STOCKS NEWS US-Europe could delay Oracle-Sun deal: sources

    Forbes.com - 9/01/09 - View Story

  • STOCKS NEWS US-BMO starts coverage on grocery stores

    CNBC - 9/01/09 - View Story

  • STOCKS NEWS US-Raytheon plans to buy BBN Technologies

    CNBC - 9/01/09 - View Story

  • Biovail 'disappointed' by clinical trial of drug to treat Parkinson's psychosis

    Yahoo! Canada - 9/01/09 - View Story

  • STOCKS NEWS US-Raytheon plans to buy BBN Technologies

    Forbes.com - 9/01/09 - View Story

  • STOCKS NEWS US-CIT shares down, co. defers interest payment

    Forbes.com - 9/01/09 - View Story

  • UPDATE 2-Acadia psychosis drug misses main goal; shrs sink

    Reuters - 9/01/09 - View Story

  • Biovail Announces Results from ACADIA's Phase III Trial of Pimavanserin in Parkinson's Disease...

    Forbes.com - 9/01/09 - View Story

  • Biovail Announces Results from ACADIAs Phase III Trial of Pimavanserin in Parkinsons Disease Psychosis

    Business Wire - 9/01/09 - View Story

  • Biovail to Purchase Rights to Develop and Commercialize JP-1730/Fipamezole in North America

    TradingMarkets - 8/26/09 - View Story

  • Biovail acquires rights to Parkinson's drug

    Globe Investor - 8/25/09 - View Story

  • Biovail acquires U.S., Canadian rights to drug to treat Parkinson’s disease

    Moose Jaw Times-Herald - 8/24/09 - View Story

  • Biovail acquires U.S., Canadian rights to drug to treat Parkinson's disease

    570News - 8/24/09 - View Story

  • Biovail acquires U.S., Canadian rights to drug to treat Parkinson's disease

    Canadian Business Magazine - 8/24/09 - View Story

  • Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera

    Therapeutics Daily - 8/24/09 - View Story

  • Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera

    Pharma Live - 8/24/09 - View Story